RayKnowChina Research Map
Shortlist

Not yet recruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Second Hospital of Dalian Medical University; 1 other hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 2

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSecond Hospital of Dalian Medical University大连医科大学附属第二医院DalianHospital page
  2. Study siteShengjing Hospital of China Medical University中国医科大学附属盛京医院ShenyangHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06820762, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed SCLC;

    Inclusion criterion 2

  3. At least one measurable lesion is present according to the efficacy evaluation criteria for RECIST 1.1(Lesions that have received radiotherapy within 6 months prior to the first dose cannot be used as target lesions)

    Inclusion criterion 6

    No untreated central nervous system (CNS) metastases or CNS were stable for ≥1 month after treatment

    Inclusion criterion 7

    All female must have had a negative serum pregnancy test within 72 hours of the first dosing and not be lactating, and study participants and their partners must use effective contraception during the trial and for 6 months after the last dosing of the trial drug.

    Inclusion criterion 9

  4. The Eastern Cancer Cooperative Group (ECOG) performance score of 0 or 1;

    Inclusion criterion 4

  5. Patients with other cancer in 3 years,exceptions are adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06820762, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥18 years;
  • Histologically or cytologically confirmed SCLC;
  • Advanced SCLC who failed first-line platinum-based chemotherapy with or without checkpoint inhibitors;
  • The Eastern Cancer Cooperative Group (ECOG) performance score of 0 or 1;
  • Life expectancy of ≥3 months;
  • At least one measurable lesion is present according to the efficacy evaluation criteria for RECIST 1.1(Lesions that have received radiotherapy within 6 months prior to the first dose cannot be used as target lesions)
  • No untreated central nervous system (CNS) metastases or CNS were stable for ≥1 month after treatment
  • Have adequate organ function;
  • All female must have had a negative serum pregnancy test within 72 hours of the first dosing and not be lactating, and study participants and their partners must use effective contraception during the trial and for 6 months after the last dosing of the trial drug.
  • Able and willing to provide a written informed consent;

Exclusion Criteria:

  • Known allergy to irinotecan hydrochloride liposome injection (II) and eboxizumab or drug excipients
  • History of severe active autoimmune disease
  • Participated in other drug studies within 4 weeks before enrollment
  • Imaging during the screening period showed that the tumor surrounded important blood vessels or had significant necrosis and voids, and the investigators determined that entering the study would cause bleeding risk
  • History of major illness within 1 year before the first medication
  • History of esophageal and gastric varices, severe ulcers, unhealed wounds, abdominal fistula, intraperitoneal abscess, or acute gastrointestinal bleeding within 6 months prior to initial administration
  • History of surgery or severe trauma within 4 weeks prior to initial dosing
  • Evidence and history of severe bleeding tendency;
  • Participants who had received or planned to receive a live vaccine within 4 weeks prior to the first study treatment
  • Patients with other cancer in 3 years,exceptions are adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
  • History of alcohol abuse, psychotropic substance abuse or drug abuse. Other conditions considered unsuitable for this study by the investigator.

Quoted from ClinicalTrials.gov, NCT06820762, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06820762, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06820762